The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease
Open accessAbstract
Introduction: This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease (CD). Patients and methods: Forty five patients with a CD activity index (CDAI) of 250–450 were randomised in a double blind, placebo controlled, dose escalating fashion to receive single doses of fontolizumab (0.1, 1.0, and 4.0 mg/kg) or placebo. By day 29, patients with clinical response were re-randomised to receive three additional doses of one half their initial fontolizumab dose or placebo at four weekly intervals. Primary objectives were safety and tolerability. Secondary outcomes included assessments of immunogenicity, clinical activity, and potential pharmacodynamic surrogates. Results: Treatment was generally well tolerated. There were slightly more reports of chills, flu-like syndrome, asthenia, nausea, and vomiting in the 1.0 mg and 4.0 mg/kg fontolizumab cohorts. Two serious adverse events rated as worsening of CD occurred under fontolizumab. Antibodies to fontolizumab were confirmed in one patient. No differences in clinical activity parameters were noted between any of the active treatment groups and placebo, with the placebo group having a particularly favourable outcome (60% response and 40% remission). By day 29, a more enhanced decrease in median Crohn’s disease endoscopic index of severity (p = 0.02) and serum C reactive protein (p<0.001) was observed in the 4.0 mg/kg (n = 14) fontolizumab cohort compared with placebo (n = 10). Pharmacodynamic effects were observed by immunohistochemistry. Conclusions: Fontolizumab was well tolerated with minimal immunogenicity at doses of up to 4.0 mg/kg in patients with CD. A biological activity of fontolizumab is suggested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Su, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.024 · Cited by 212
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationCytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 473
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy
de Souza, H. S. P., Fiocchi, C., & Iliopoulos, D. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.110 · Cited by 447
Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R., & Weaver, C. T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415675112 · Cited by 427
LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens
Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., Korzenik, J. R., Rioux, J. D., Daly, M. J., Xavier, R. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000548 · Cited by 415
Biological Therapies for Inflammatory Bowel Diseases
Rutgeerts, P., Vermeire, S., & Van Assche, G. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.001 · Cited by 363
Self-citationDifferential regulation of interleukin 17 and interferon production in inflammatory bowel disease
Rovedatti, L., Kudo, T., Biancheri, P., Sarra, M., Knowles, C. H., Rampton, D. S., Corazza, G. R., Monteleone, G., Di Sabatino, A., & MacDonald, T. T. (2009) · Gut · doi:10.1136/gut.2009.182170 · Cited by 338
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
New therapies for inflammatory bowel disease: from the bench to the bedside
Danese, S. (2012) · Gut · doi:10.1136/gutjnl-2011-300904 · Cited by 308
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 281
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Self-citationLanger, V., Vivi, E., Regensburger, D., Winkler, T. H., Waldner, M. J., Rath, T., Schmid, B., Skottke, L., Lee, S., Jeon, N. L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124884 · Cited by 256
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice
Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.003 · Cited by 217
Self-citationT lymphocytes in the intestinal mucosa: defense and tolerance
Ma, H., Tao, W., & Zhu, S. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0208-2 · Cited by 125
Metadata
- Authors
- Reinisch, W., Hommes, D. W., Van Assche, G., Colombel, J.-F., Gendre, J.-P., Oldenburg, B., Teml, A., Geboes, K., Ding, H., Zhang, L., Tang, M., Cheng, M., van Deventer, S. J. H., Rutgeerts, P., & Pearce, T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-02-21
- Volume
- 55
- Issue
- 8
- Pages
- 1138-1144
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2122516118
- Cited by
- 175
- References
- 1
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.